Abstract
The virtual molecular library contains phenolic group at the intermediate stage was investigated which having a potency to treat Type 2 Diabetes Mellitus. The designed molecules have shown comparable in-silico binding affinity to marketed thiazolidinedione (TZD) class of drug toward peroxisome proliferator activated receptor-γ (PPAR-γ) protein. Interestingly, change of phenolic group with 5-hydroxy quinolone in pioglitazone has shown high structural conservation in PPAR-γ ligand binding domain (LBD) with pioglitazone having better affinity. This information might be very useful to identify novel lead compounds for further development toward Type 2 Diabetes Mellitus treatment targeting PPAR-γ.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
